Sandoz Gains European Approval for First Generic Biologic

Scott, Alex
May 2006
Chemical Week;5/3/2006, Vol. 168 Issue 15, p22
Trade Publication
The article reports on the authorization given by the European Commission for the use of Omnitrope, Sandoz's generic biologic human growth hormone, across the European Union. The authorization is the first approval in Europe of a generic biologic, otherwise known as biogeneric or biosimilar, and is likely to pave the way for a wave of biogeneric approvals in the next few years, experts say.


Related Articles

  • Epo, by any other name.  // Nature;9/20/2007, Vol. 449 Issue 7160, p259 

    The article reports that three companies for generic versions of the hormone erythropoietin had been granted marketing authorizations by the European Commission. The three companies include Amgen Inc., Johnson & Johnson and Sandoz AG. The approvals bring to five the number of follow-on...

  • Commentary: Sector inquiry into the pharmaceutical sector. Besen, Marc; Slobodenjuk, Dimitri // Journal of Business Chemistry;Sep2008, Vol. 5 Issue 3, p81 

    The authors reflect on the sector inquiry into the pharmaceutical industry concerning the introduction of innovative and generic medicines onto the market in the European Union. Information on the European Commission's sector inquiry is provided. The authors expect a recommendation from the...

  • Time is ticking on EU drug directive. STOBIE, CRAIG // Packaging News;Oct2014, p42 

    The article focuses on significance of the Falsified Medicines Directive of the European Commission for the manufacturers of generic drugs , citing concerns of European Generics Association regarding the issue and offers suggestions for the manufacturers regarding management of production.

  • Whatever Happened To Faster Reimbursement For Generics In Europe? Reflector // Pharmaceutical Executive;Apr2014, Vol. 34 Issue 4, p16 

    The article discusses the implications of the pricing and reimbursement rules imposed by the European Union (EU) for generic drugs in Europe. It states that these rules was a factor in the delay of generic medicines to the European market according to a research by the European Commission....

  • AstraZeneca Plc, GlaxoSmithKline Plc, Sanofi-Aventis SA and other drugmakers have received queries from the European Union as part of a probe into strategies that may keep cheaper copies of medicines off the market.  // MondayMorning;1/18/2010, Vol. 18 Issue 2, p19 

    The article reports on the move of the European Commission (EC) to investigate ways to keep off cheaper copies of medicines in the European market. The European Union (EU) has sent questionnaires to pharmaceutical companies that include AstraZeneca PLC and GlaxoSmithKline PLC to obtain...

  • FDA Clears Way for More Generics to Enter Market.  // Chain Drug Review;5/19/2014, Vol. 36 Issue 8, p70 

    The article offers information on launch and U.S. Food and Drug Administration's approval for several generic drugs including U.S. market introduction of generic version of Leo Pharma's Taclonex ointment and amoxicillin capsules by Sandoz, and launch of Greenstone LLC's piroxicam capsules.

  • EGA position on the EC's proposal for a falsified medicines directive. Markova, Ilina // Pharmaceutical Technology Europe;Oct2010, Vol. 22 Issue 10, p51 

    The article discusses the adoption of a European Commission (EC) proposal for a Directive on the falsification of medicines by the European Generic Medicines Association (EGA). It explores two provisions relevant to the European generic medicines industry identified by the EGA. It cites EGA's...

  • Pharma Accused of Keeping Good Generics Down. Houlton, Sarah // Pharmaceutical Executive;Aug2009, Vol. 29 Issue 8, p14 

    The article reports that the pharmaceutical industry was accused of delaying the entry of generic drugs to the market by the European Commission. In response, the commission will investigate the sector under European Union antitrust law. According to Competition Commissioner Neelie Kroes, the...

  • Legal And Regulatory Update.  // Journal of Commercial Biotechnology;Apr2010, Vol. 16 Issue 2, p174 

    The article presents updates related to patent regulations of the European Union (EU). In its final report on the Pharmaceutical Sector Inquiry, the European Commission expressed its concerns regarding patent settlement agreements between originator and generic companies, and the report stated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics